Scalper1 News
Specialty-drug giant Actavis (ACT) is due to report another quarter of growth, before the market open Wednesday, as the IBD 50 stock continues to swell through acquisitions. Analysts polled by Thomson Reuters estimate Actavis made $3.24 a share in the quarter, up 63% from the year-earlier quarter. Sales were estimated to grow 36.5% to $2.59 billion. Actavis hasn’t given any guidance for the year, saying it will wait until it completes its Scalper1 News
Scalper1 News